LABA/LAMA glucocorticoid combination (triple therapy)
Jump to navigation
Jump to search
Indications
- maintenance treatment of moderate to severe COPD
- predominantly benefits patients with elevated blood eosinophil count (> 300 x 10E6/L)[1]
Laboratory
- complete blood count
- eosinophil count: > 300 x 10E6/L
More general terms
More specific terms
- budesonide/formoterol/glycopyrrolate (Breztri Aerosphere)
- fluticasone/umeclidinium/vilanterol (Trelegy Ellipta)
- formoterol/fumarate/mometasone
Components
- long-acting beta adrenergic receptor agonist (LABA)
- long-acting muscarinic receptor antagonist (LAMA)
- inhaled glucocorticoid
References
- ↑ Jump up to: 1.0 1.1 Labaki WW, Rosenberg SR. Chronic obstructive pulmonary disease. Ann Intern Med 2020 Aug 4; 173:ITC17 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32745458
Agusti A, Celli BR, Criner GJ et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD executive summary. Am J Respir Crit Care Med. 2023 Apr 1;207(7):819-837. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36856433 PMCID: PMC10111975 Free PMC article https://www.atsjournals.org/doi/10.1164/rccm.202301-0106PP